Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Nemluvio

    - PMLiVE

    Galderma’s Nemluvio rapidly relieves atopic dermatitis and prurigo nodularis symptoms

    Some patients found the treatment reduced itch and sleep disturbance within just two days

    - PMLiVE

    Apogee Therapeutics’ atopic dermatitis candidate shows promise in phase 2 study

    The inflammatory skin condition affects over 26 million people in the US

    - PMLiVE

    Eli Lilly/Almirall’s Ebglyss shows promise in atopic dermatitis patients with darker skin tones

    The inflammatory skin condition occurs in approximately 7.3% of adults in the US

    - PMLiVE

    Galderma shares positive long-term data for Nemluvio in prurigo nodularis

    The chronic skin disorder is estimated to affect up to 181,000 people in the US

    - PMLiVE

    Sanofi/Regeneron share results for Dupixent in atopic dermatitis patients with darker skin tones

    These are the first clinical study results for the drug in a large population of patients with darker skin tones

    - PMLiVE

    Galderma shares positive two-year results for Nemluvio in atopic dermatitis

    The chronic inflammatory skin disease affects more than 230 million people worldwide

    - PMLiVE

    Amgen/Kyowa Kirin share promising phase 3 results for rocatinlimab in atopic dermatitis

    The inflammatory skin disease affects up to 20% of children and 10% of adults worldwide

    - PMLiVE

    Organon shares positive long-term results for Vtama cream in atopic dermatitis

    The common inflammatory skin disease affects more than 26 million people in the US alone

    - PMLiVE

    MHRA approves Galderma’s Nemluvio to treat atopic dermatitis and prurigo nodularis

    The drug has been authorised to treat patients with moderate-to-severe cases of the skin diseases

    EU flag

    EC approves Galderma’s Nemluvio to treat atopic dermatitis and prurigo nodularis

    Nemluvio is now the first approved monoclonal antibody that specifically targets interleukin-31 receptor alpha

    - PMLiVE

    Gilead and LEO enter inflammatory disease partnership worth up to $1.7bn

    Targeting STAT6 has shown potential in treating a broad population of inflammatory disease patients

    - PMLiVE

    J&J expands atopic dermatitis pipeline with Kaken Pharmaceutical licensing deal

    The inflammatory skin disorder affects more than 9.6 million children and 16.5 million adults in the US

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links